tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Abnormalities, Multiple D000015 13 associated lipids
Abortion, Spontaneous D000022 12 associated lipids
Acne Vulgaris D000152 35 associated lipids
Adenocarcinoma D000230 166 associated lipids
Adrenal Insufficiency D000309 3 associated lipids
Akinetic Mutism D000405 1 associated lipids
Albuminuria D000419 18 associated lipids
Alopecia D000505 14 associated lipids
Alopecia Areata D000506 6 associated lipids
Alzheimer Disease D000544 76 associated lipids
Amenorrhea D000568 4 associated lipids
Amputation, Traumatic D000673 2 associated lipids
Anemia D000740 21 associated lipids
Anemia, Aplastic D000741 6 associated lipids
Anemia, Hemolytic D000743 4 associated lipids
Anemia, Hemolytic, Autoimmune D000744 5 associated lipids
Anemia, Refractory D000753 3 associated lipids
Anemia, Refractory, with Excess of Blasts D000754 2 associated lipids
Aneurysm, Dissecting D000784 2 associated lipids
Angiolymphoid Hyperplasia with Eosinophilia D000796 1 associated lipids
Angioedema D000799 6 associated lipids
Anus Diseases D001004 3 associated lipids
Apraxias D001072 1 associated lipids
Arm Injuries D001134 1 associated lipids
Arterial Occlusive Diseases D001157 12 associated lipids
Arteriosclerosis D001161 86 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Arthritis, Infectious D001170 8 associated lipids
Arthritis, Juvenile D001171 8 associated lipids
Ascites D001201 25 associated lipids
Ataxia D001259 20 associated lipids
Ataxia Telangiectasia D001260 6 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Autonomic Nervous System Diseases D001342 4 associated lipids
Bacterial Infections D001424 21 associated lipids
Balanitis D001446 4 associated lipids
Beckwith-Wiedemann Syndrome D001506 1 associated lipids
Behcet Syndrome D001528 7 associated lipids
Biliary Fistula D001658 13 associated lipids
Biliary Tract Neoplasms D001661 7 associated lipids
Blepharitis D001762 4 associated lipids
Blindness D001766 6 associated lipids
Body Weight D001835 333 associated lipids
Bone Diseases D001847 4 associated lipids
Bradycardia D001919 13 associated lipids
Brain Diseases D001927 27 associated lipids
Brain Edema D001929 20 associated lipids
Bronchiolitis D001988 6 associated lipids
Bronchiolitis Obliterans D001989 8 associated lipids
Burkitt Lymphoma D002051 15 associated lipids
Burns D002056 34 associated lipids
Candidiasis, Oral D002180 11 associated lipids
Candidiasis, Vulvovaginal D002181 8 associated lipids
Carcinoma, Squamous Cell D002294 14 associated lipids
Cardiomyopathy, Hypertrophic D002312 6 associated lipids
Cardiomyopathy, Restrictive D002313 1 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Carpal Tunnel Syndrome D002349 3 associated lipids
Catalepsy D002375 30 associated lipids
Cataract D002386 34 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Myoclonic Cerebellar Dyssynergia D002527 1 associated lipids
Brain Ischemia D002545 89 associated lipids
Ischemic Attack, Transient D002546 42 associated lipids
Cerebrovascular Disorders D002561 25 associated lipids
Uterine Cervical Dysplasia D002578 2 associated lipids
Cheilitis D002613 2 associated lipids
Cholelithiasis D002769 16 associated lipids
Cholestasis D002779 23 associated lipids
Choline Deficiency D002796 16 associated lipids
Hemophilia B D002836 3 associated lipids
Chronic Disease D002908 7 associated lipids
Cicatrix D002921 9 associated lipids
Coccidioidomycosis D003047 2 associated lipids
Colitis D003092 69 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Collagen Diseases D003095 2 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Confusion D003221 4 associated lipids
Connective Tissue Diseases D003240 2 associated lipids
Corneal Diseases D003316 13 associated lipids
Cough D003371 19 associated lipids
Crigler-Najjar Syndrome D003414 1 associated lipids
Crohn Disease D003424 12 associated lipids
Cryptococcosis D003453 3 associated lipids
Cutis Laxa D003483 1 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Cystitis D003556 23 associated lipids
Phyllodes Tumor D003557 1 associated lipids
Hearing Loss, Sudden D003639 1 associated lipids
Deglutition Disorders D003680 2 associated lipids
Dehydration D003681 11 associated lipids
Demyelinating Diseases D003711 15 associated lipids
Dental Enamel Hypoplasia D003744 2 associated lipids
Dental Pulp Calcification D003784 2 associated lipids
Dermatitis D003872 30 associated lipids
Drug Eruptions D003875 30 associated lipids
Dermatitis, Atopic D003876 19 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Woodward RS et al. Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. 2003 Am. J. Transplant. pmid:12752315
Lehmann R et al. Successful simultaneous islet-kidney transplantation using a steroid-free immunosuppression: two-year follow-up. 2004 Am. J. Transplant. pmid:15196070
Axelrod D et al. Reduction of CMV disease with steroid-free immunosuppresssion in simultaneous pancreas-kidney transplant recipients. 2005 Am. J. Transplant. pmid:15888050
Reyes J et al. Intestinal transplantation under tacrolimus monotherapy after perioperative lymphoid depletion with rabbit anti-thymocyte globulin (thymoglobulin). 2005 Am. J. Transplant. pmid:15888051
Knoop C et al. Tacrolimus pharmacokinetics and dose monitoring after lung transplantation for cystic fibrosis and other conditions. 2005 Am. J. Transplant. pmid:15888057
Kim EJ et al. Costimulation blockade alters germinal center responses and prevents antibody-mediated rejection. 2014 Am. J. Transplant. pmid:24354871
Kandaswamy R et al. A prospective randomized trial of steroid-free maintenance regimens in kidney transplant recipients--an interim analysis. 2005 Am. J. Transplant. pmid:15888064
Frassetto LA et al. Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. 2007 Am. J. Transplant. pmid:17949460
Cosio FG and Larson TS Cardiovascular disease after transplantation: do we know all of the variables? 2003 Am. J. Transplant. pmid:12859523
Krämer BK et al. Cardiovascular risk factors and estimated risk for CAD in a randomized trial comparing calcineurin inhibitors in renal transplantation. 2003 Am. J. Transplant. pmid:12859533
Ciancio G et al. The use of daclizumab, tacrolimus and mycophenolate mofetil in african-american and Hispanic first renal transplant recipients. 2003 Am. J. Transplant. pmid:12859538
Cavadas PC et al. Bilateral trans-humeral arm transplantation: result at 2 years. 2011 Am. J. Transplant. pmid:21521475
Xu H et al. The allo- and viral-specific immunosuppressive effect of belatacept, but not tacrolimus, attenuates with progressive T cell maturation. 2014 Am. J. Transplant. pmid:24472192
Qazi Y et al. Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Data. 2017 Am. J. Transplant. pmid:27775865
Coghill AE et al. Immunosuppressive Medications and Squamous Cell Skin Carcinoma: Nested Case-Control Study Within the Skin Cancer after Organ Transplant (SCOT) Cohort. 2016 Am. J. Transplant. pmid:26824445
Song L et al. ASP2409, A Next-Generation CTLA4-Ig, Versus Belatacept in Renal Allograft Survival in Cynomolgus Monkeys. 2017 Am. J. Transplant. pmid:27598231
Kurtz J et al. Lack of role for CsA-sensitive or Fas pathways in the tolerization of CD4 T cells via BMT and anti-CD40L. 2003 Am. J. Transplant. pmid:12814472
Egli A et al. Renal failure five years after lung transplantation due to polyomavirus BK-associated nephropathy. 2010 Am. J. Transplant. pmid:20840474
Zafrani L et al. Incidence, risk factors and clinical consequences of neutropenia following kidney transplantation: a retrospective study. 2009 Am. J. Transplant. pmid:19538494
Touzot M et al. Renal transplantation in HIV-infected patients: the Paris experience. 2010 Am. J. Transplant. pmid:20840478
Krämer BK et al. Tacrolimus once daily (ADVAGRAF) versus twice daily (PROGRAF) in de novo renal transplantation: a randomized phase III study. 2010 Am. J. Transplant. pmid:20840480
Trunečka P et al. Once-daily prolonged-release tacrolimus (ADVAGRAF) versus twice-daily tacrolimus (PROGRAF) in liver transplantation. 2010 Am. J. Transplant. pmid:20840481
Ekberg H et al. Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation. 2009 Am. J. Transplant. pmid:19563339
Mehra MR et al. Immunosuppression in cardiac transplantation: science, common sense and the heart of the matter. 2006 Am. J. Transplant. pmid:16686745
Grimm M et al. Superior prevention of acute rejection by tacrolimus vs. cyclosporine in heart transplant recipients--a large European trial. 2006 Am. J. Transplant. pmid:16686762
Budde K et al. Novel once-daily extended-release tacrolimus (LCPT) versus twice-daily tacrolimus in de novo kidney transplants: one-year results of Phase III, double-blind, randomized trial. 2014 Am. J. Transplant. pmid:25278376
Sis B et al. Reproducibility studies on arteriolar hyaline thickening scoring in calcineurin inhibitor-treated renal allograft recipients. 2006 Am. J. Transplant. pmid:16686769
Duncan FJ et al. Clinically relevant immunosuppressants influence UVB-induced tumor size through effects on inflammation and angiogenesis. 2007 Am. J. Transplant. pmid:17941958
Hu X et al. Chimeric Allografts Induced by Short-Term Treatment With Stem Cell-Mobilizing Agents Result in Long-Term Kidney Transplant Survival Without Immunosuppression: A Study in Rats. 2016 Am. J. Transplant. pmid:26749344
Cameron AM et al. Chimeric Allografts Induced by Short-Term Treatment With Stem Cell Mobilizing Agents Result in Long-Term Kidney Transplant Survival Without Immunosuppression: II, Study in Miniature Swine. 2016 Am. J. Transplant. pmid:26748958
O'Grady JG et al. Randomized controlled trial of tacrolimus versus microemulsified cyclosporin (TMC) in liver transplantation: poststudy surveillance to 3 years. 2007 Am. J. Transplant. pmid:17109723
Böhmig GA et al. Immunoadsorption in severe C4d-positive acute kidney allograft rejection: a randomized controlled trial. 2007 Am. J. Transplant. pmid:17109725
Budde K et al. Sotrastaurin, a novel small molecule inhibiting protein kinase C: first clinical results in renal-transplant recipients. 2010 Am. J. Transplant. pmid:20121745
Hanto DW et al. Intraoperative administration of inhaled carbon monoxide reduces delayed graft function in kidney allografts in Swine. 2010 Am. J. Transplant. pmid:20977633
Al-Massarani G et al. Impact of immunosuppressive treatment on endothelial biomarkers after kidney transplantation. 2008 Am. J. Transplant. pmid:18925903
Bouamar R et al. Tacrolimus predose concentrations do not predict the risk of acute rejection after renal transplantation: a pooled analysis from three randomized-controlled clinical trials(†). 2013 Am. J. Transplant. pmid:23480233
Busque S et al. The PROMISE study: a phase 2b multicenter study of voclosporin (ISA247) versus tacrolimus in de novo kidney transplantation. 2011 Am. J. Transplant. pmid:21943027
Hamdy AF et al. Comparison of sirolimus with low-dose tacrolimus versus sirolimus-based calcineurin inhibitor-free regimen in live donor renal transplantation. 2005 Am. J. Transplant. pmid:16162204
Kaufman DB et al. Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction--long-term results. 2005 Am. J. Transplant. pmid:16162205
Naesens M et al. Tacrolimus exposure and evolution of renal allograft histology in the first year after transplantation. 2007 Am. J. Transplant. pmid:17608835
Schwarz A et al. Polyoma virus nephropathy in native kidneys after lung transplantation. 2005 Am. J. Transplant. pmid:16162212
Shemesh E et al. The Medication Level Variability Index (MLVI) Predicts Poor Liver Transplant Outcomes: A Prospective Multi-Site Study. 2017 Am. J. Transplant. pmid:28321975
Schold JD The burden of proof in the design of early phase clinical trials. 2013 Am. J. Transplant. pmid:23802723
Chisholm-Burns MA et al. Improving outcomes of renal transplant recipients with behavioral adherence contracts: a randomized controlled trial. 2013 Am. J. Transplant. pmid:23819827
Troppmann C et al. Impact of portal venous pancreas graft drainage on kidney graft outcome in simultaneous pancreas-kidney recipients reported to UNOS. 2004 Am. J. Transplant. pmid:15023146
Muthusamy AS et al. Alemtuzumab induction and steroid-free maintenance immunosuppression in pancreas transplantation. 2008 Am. J. Transplant. pmid:18828772
Van Laecke S et al. Posttransplantation hypomagnesemia and its relation with immunosuppression as predictors of new-onset diabetes after transplantation. 2009 Am. J. Transplant. pmid:19624560
Pirenne J et al. Tolerance of liver transplant patients to strenuous physical activity in high-altitude. 2004 Am. J. Transplant. pmid:15023147
Heisel O et al. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. 2004 Am. J. Transplant. pmid:15023151
Hardinger KL et al. Pharmacokinetics of tacrolimus in kidney transplant recipients: twice daily versus once daily dosing. 2004 Am. J. Transplant. pmid:15023155
Suwelack B et al. Withdrawal of cyclosporine or tacrolimus after addition of mycophenolate mofetil in patients with chronic allograft nephropathy. 2004 Am. J. Transplant. pmid:15023160
Srinivas TR et al. The noninferiority trial: don't don't do it. 2010 Am. J. Transplant. pmid:21087412
Pescovitz MD et al. A randomized, double-blind, pharmacokinetic study of oral maribavir with tacrolimus in stable renal transplant recipients. 2009 Am. J. Transplant. pmid:19663892
Bryan CF et al. Long-term survival of kidneys transplanted from live A2 donors to O and B recipients. 2007 Am. J. Transplant. pmid:17359511
Vincenti F et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. 2007 Am. J. Transplant. pmid:17359512
Diaz-Siso JR et al. Initial experience of dual maintenance immunosuppression with steroid withdrawal in vascular composite tissue allotransplantation. 2015 Am. J. Transplant. pmid:25777324
Senior PA et al. Proteinuria developing after clinical islet transplantation resolves with sirolimus withdrawal and increased tacrolimus dosing. 2005 Am. J. Transplant. pmid:16095517
Meier-Kriesche HU and Kaplan B Cyclosporine microemulsion and tacrolimus are associated with decreased chronic allograft failure and improved long-term graft survival as compared with sandimmune. 2002 Am. J. Transplant. pmid:12095048
Rodriguez-Rodriguez AE et al. The higher diabetogenic risk of tacrolimus depends on pre-existing insulin resistance. A study in obese and lean Zucker rats. 2013 Am. J. Transplant. pmid:23651473
Klintmalm GB et al. Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II randomized study. 2014 Am. J. Transplant. pmid:25041339
Jaksch P et al. Alemtuzumab in lung transplantation: an open-label, randomized, prospective single center study. 2014 Am. J. Transplant. pmid:25039364
Neuberger JM et al. Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the 'ReSpECT' study. 2009 Am. J. Transplant. pmid:19120077
Momper JD et al. The impact of conversion from prograf to generic tacrolimus in liver and kidney transplant recipients with stable graft function. 2011 Am. J. Transplant. pmid:21714845
TruneÄŒka P et al. Renal Function in De Novo Liver Transplant Recipients Receiving Different Prolonged-Release Tacrolimus Regimens-The DIAMOND Study. 2015 Am. J. Transplant. pmid:25707487
Adam R et al. Improved survival in liver transplant recipients receiving prolonged-release tacrolimus in the European Liver Transplant Registry. 2015 Am. J. Transplant. pmid:25703527
Asrani SK and O'Leary JG Can one pill a day keep rejection away? 2015 Am. J. Transplant. pmid:25703394
Oetting WS et al. Genomewide Association Study of Tacrolimus Concentrations in African American Kidney Transplant Recipients Identifies Multiple CYP3A5 Alleles. 2016 Am. J. Transplant. pmid:26485092
Badri P et al. Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir. 2015 Am. J. Transplant. pmid:25708713
Borrows R et al. Mycophenolic acid 12-h trough level monitoring in renal transplantation: association with acute rejection and toxicity. 2006 Am. J. Transplant. pmid:16433766
Kohnle M et al. Ezetimibe for the treatment of uncontrolled hypercholesterolemia in patients with high-dose statin therapy after renal transplantation. 2006 Am. J. Transplant. pmid:16433776
Larson TS et al. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. 2006 Am. J. Transplant. pmid:16468960
Vitko S et al. Tacrolimus combined with two different dosages of sirolimus in kidney transplantation: results of a multicenter study. 2006 Am. J. Transplant. pmid:16468962
Russ GR et al. Efficacy of sotrastaurin plus tacrolimus after de novo kidney transplantation: randomized, phase II trial results. 2013 Am. J. Transplant. pmid:23668931
Rodríguez-Perálvarez M et al. Tacrolimus trough levels, rejection and renal impairment in liver transplantation: a systematic review and meta-analysis. 2012 Am. J. Transplant. pmid:22703529
Luan FL et al. Comparative risk of impaired glucose metabolism associated with cyclosporine versus tacrolimus in the late posttransplant period. 2008 Am. J. Transplant. pmid:18786231
Woywodt A et al. Different preparations of tacrolimus and medication errors. 2008 Am. J. Transplant. pmid:18786238
Servais A et al. Interstitial fibrosis evolution on early sequential screening renal allograft biopsies using quantitative image analysis. 2011 Am. J. Transplant. pmid:21672152
Senior PA et al. Changes in renal function after clinical islet transplantation: four-year observational study. 2007 Am. J. Transplant. pmid:17227560
Carenco C et al. Tacrolimus and the risk of solid cancers after liver transplant: a dose effect relationship. 2015 Am. J. Transplant. pmid:25648361
Levi Z et al. Switching from tacrolimus to sirolimus halts the appearance of new sebaceous neoplasms in Muir-Torre syndrome. 2007 Am. J. Transplant. pmid:17229076
Mulay AV et al. Impact of immunosuppressive medication on the risk of renal allograft failure due to recurrent glomerulonephritis. 2009 Am. J. Transplant. pmid:19353768
Ogawa T et al. Rho-associated kinase inhibitor reduces tumor recurrence after liver transplantation in a rat hepatoma model. 2007 Am. J. Transplant. pmid:17229077
Miriuka SG et al. mTOR inhibition induces endothelial progenitor cell death. 2006 Am. J. Transplant. pmid:16796720
Bourdeaux C et al. Living-related versus deceased donor pediatric liver transplantation: a multivariate analysis of technical and immunological complications in 235 recipients. 2007 Am. J. Transplant. pmid:17173657
Heller T et al. Plasma concentrations of mycophenolic acid acyl glucuronide are not associated with diarrhea in renal transplant recipients. 2007 Am. J. Transplant. pmid:17532750
Schrepfer S et al. Effect of inhaled tacrolimus on cellular and humoral rejection to prevent posttransplant obliterative airway disease. 2007 Am. J. Transplant. pmid:17532751
Ryan CM and Swanson DP clinical research, innovative practice and IRB review: identifying and respecting boundaries. 2007 Am. J. Transplant. pmid:17331113
Rostaing L et al. Alefacept combined with tacrolimus, mycophenolate mofetil and steroids in de novo kidney transplantation: a randomized controlled trial. 2013 Am. J. Transplant. pmid:23730730
Grinyo JM et al. Pilot randomized study of early tacrolimus withdrawal from a regimen with sirolimus plus tacrolimus in kidney transplantation. 2004 Am. J. Transplant. pmid:15268733
Schussler T et al. Severe hepatitis C infection in a renal transplant recipient following hepatitis C genotype mismatch transplant. 2004 Am. J. Transplant. pmid:15268744
Levy G et al. REFINE: a randomized trial comparing cyclosporine A and tacrolimus on fibrosis after liver transplantation for hepatitis C. 2014 Am. J. Transplant. pmid:24456049
Posselt AM et al. Islet transplantation in type 1 diabetics using an immunosuppressive protocol based on the anti-LFA-1 antibody efalizumab. 2010 Am. J. Transplant. pmid:20659093
Pradhan M et al. Decline in renal function following thoracic organ transplantation in children. 2002 Am. J. Transplant. pmid:12201367
Ciancio G et al. Advantage of rapamycin over mycophenolate mofetil when used with tacrolimus for simultaneous pancreas kidney transplants: randomized, single-center trial at 10 years. 2012 Am. J. Transplant. pmid:22946986
Jacobson PA et al. Lower calcineurin inhibitor doses in older compared to younger kidney transplant recipients yield similar troughs. 2012 Am. J. Transplant. pmid:22947444
De Simone P et al. Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. 2012 Am. J. Transplant. pmid:22882750
Echeverri GJ et al. Endoscopic gastric submucosal transplantation of islets (ENDO-STI): technique and initial results in diabetic pigs. 2009 Am. J. Transplant. pmid:19775318
Gaston RS et al. Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trial. 2009 Am. J. Transplant. pmid:19459794
Lake JR et al. Addition of MMF to dual immunosuppression does not increase the risk of malignant short-term death after liver transplantation. 2005 Am. J. Transplant. pmid:16303011
Pallet N et al. Long-Term Clinical Impact of Adaptation of Initial Tacrolimus Dosing to CYP3A5 Genotype. 2016 Am. J. Transplant. pmid:26990694